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Abstract
Retrospective analysis of 3984 test results for the detection of
Mycoplasma pneumoniae performed between 2009 and 2013 in
Wales was undertaken. Analysis of the clinical presentation of
positive cases suggested that mild respiratory infection was
common in the community and appeared to coincide with
increased hospitalizations. Symptomatic infection was more
prevalent in men, with a median age of 22.6 years (range <1–
88 years), and 40% of hospitalized cases presented with pneumo-
nia. Inclusion of M. pneumonia nucleic acid ampliﬁcation tests
(NAATs) into routine respiratory NAAT screens will increase the
understanding of the epidemiology and clinical spectrum of acute
infections in the wider population.
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Introduction
Mycoplasma pneumoniae is a signiﬁcant cause of commu-
nity-acquired pneumonia (CAP) and is associated with chronic
respiratory illness and extrapulmonary complications such as
Steven-Johnson syndrome [1–6]. An M. pneumoniae epidemic
occurred in northern Europe from 2010 to 2012 [7–11].
An accurate diagnosis of acuteM. pneumoniae infection based
on clinical symptoms alone is difﬁcult and laboratory conﬁrma-
tion should be used to conﬁrm an infection prior to prescribing
antibiotics [12–17]. Serology is the method of choice in most
centres but the requirement of acute and convalescent sera to
demonstrate an increase in antibody titre delays time to results
and thus antibiotics may be prescribed inappropriately or not at
all [12,14–16]. IgM results should be interpreted with caution
due to non-speciﬁc reactions, including cross-reactivity between
other Mycoplasma species, and false-negative results can occur
as a result of infection in a background of immunosuppression
[16]. Conventional laboratory methods used to diagnosis acute
M. pneumoniae infection are applied in a non-standardized way
and a recognized reference standard method is needed [15].
Although speciﬁcM. pneumoniae nucleic acid ampliﬁcation tests
(NAATs) have been described, theirwidespread use is limited by
the lack of standardized quality control material and validated
algorithms, and a paucity of good quality studies combining
laboratory diagnosis with clinical features. Laboratory conﬁr-
mation ofM. pneumoniae therefore remains a challenge. [13,15].
In Wales, an M. pneumoniae NAAT was introduced in
October 2011, this study aims to describe how its introduc-
tion led to improved diagnosis and understanding of the
presenting features of acute infection in both hospital and
community settings.
A laboratory data search was undertaken to identify all
samples where an M. pneumoniae test was performed by
serology, NAAT or a combination of both between January
2009 and June 2013.
The frontline serological screen used for acute infection
was the SERODIA-MYCO II particle agglutination (PA) kit
(Fujirebio Inc., Tokyo, Japan). This was performed following
the manufacturer’s instructions, but with a titre of 1:160
considered signiﬁcant. A qualitative M. pneumoniae NAAT
targeting the conserved region of the P1 adhesin gene [18]
was optimized for use with the ABI 7500 FAST and the 4X ABI
FAST Virus mix using previously described ampliﬁcation
parameters [19,20].
Local validation of the NAAT was performed using the
M. pneumoniae 2011 QCMD panel and known positive samples.
Validation was performed on both upper and lower respiratory
tract samples. Nucleic acid was extracted with the NucliSens
EasyMag extractor (BioMerieux, Marseille, France), using
previously described methods [19,20]. The M. pneumoniae
NAAT was incorporated into the routine respiratory screen
and human RNaseP was used as a control for both nucleic acid
extraction and ampliﬁcation as previously described [19].
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Data from 3984 patients were included in the ﬁnal analysis.
Where applicable, variables were compared using Fisher’s
exact test and proportions were compared using the Z test
with a p value of <0.05 considered signiﬁcant.
Acute serological testing was undertaken for a total of 566
samples over the time period, whereas NAAT testing was
performed for 3464 samples from October 2011 until June
2013 (positivity rates 3.4%, 2011; 1.2%, 2012; 0.7%, 2013). Of
those tested by both PA and NAAT with a signiﬁcant titre by
PA, 45/46 (92%) were found to be negative by NAAT,
suggesting previous rather than acute infection. One case was
positive in two successive samples by NAAT and showed an
increase in PA titre from <40 to >1280.
Clinical data were obtained for 110 laboratory-conﬁrmed
M. pneumoniae cases. Of these, 53 were NAAT positive and 57
were positive by serology. Ages ranged from <1 year to
88 years old (median age 22.6 years) (Fig. 1). The median age
of hospitalized cases was 17.5 years, which was younger than
the median age for conﬁrmed community cases (27.3 years),
although this was not statistically signiﬁcant (Table 1).
Conﬁrmed M. pneumoniae infection was more likely in men
(p 0.004 community cases, p 0.009 hospitalized cases and p
0.03 critical care cases). Community cases were more likely to
present with a mild upper respiratory tract infection than
hospitalized cases (p <0.05). A signiﬁcantly higher proportion
of hospitalized cases (40%) presented with pneumonia
(p <0.05); this is at the higher end of previous estimates [5].
Extrapulmonary symptoms were found in hospitalized
cases, but in this study Steven-Johnson syndrome was signif-
icantly more likely in conﬁrmed cases in hospital (p 0.03). Only
2/16 cases presenting with extrapulmonary symptoms were
conﬁrmed by NAAT. In addition, a male aged 19 with
underlying asthma died in the community following a respira-
tory illness. M. pneumoniae DNA was detected in lower
respiratory tract samples collected at the post-mortem.
Over the study period, 19/144 (13%) samples received
through the sentinel surveillance scheme were positive for
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FIG. 1. Ages of those conﬁrmed asM. pneumoniae positive by serology and/or NAAT. The peak incidence occurred in the 5–14-year-old age group,
although the average age of both patients in the community and patients admitted to critical care was higher than that seen in those admitted to
general wards in the hospital. The cluster of cases that occurred in the community in south-east Wales predominantly affected people in the age
range 45–64 with one admission to critical care; this is higher than the age ranges normally associated with M. pneumoniae infection.
TABLE 1. Characteristics of laboratory-conﬁrmed M. pneu-
moniae cases
Community
(n = 36)
Hospital
(n = 58)
Critical care
(n = 16)
Age (mean years) 27.3 17.5 31
Gender
Male 24 36 11
Female 12 22 5
Symptoms
Upper respiratory tract
Cough 15 10 0
Sore throat 2 1 0
Inﬂuenza-like illnessa 15 1 0
Lower respiratory tract
Pneumonia 3 28 13
Bronchiolitis 0 2 1
Extrapulmonary
Rash 1 1 0
Neurological symptoms 0 3 0
Jaundice 0 1 0
Hepatosplenamegaly 0 1 0
Renal failure 0 1 0
Sepsis 0 1 2
Sickle cell crisis 0 1 0
Immunological
Steven-Johnson syndrome 0 7 0
aInﬂuenza-like illness is deﬁned in Wales as being an illness of sudden onset typiﬁed
by a pyrexia of >38°C and at least two other symptoms including cough, sore
throat, myalgia, fatigue, rigors and headache.
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M. pneumoniae DNA. Positivity rates in this cohort were
highest during November 2011 to January 2012, when 11/31
(35%) cases tested positive for M. pneumoniae. This may
reﬂect the latter end of the M. pneumoniae epidemic as the
overall positivity rate reduced over successive years [10].
Two distinct community clusters were identiﬁed through
the sentinel surveillance scheme. The ﬁrst centred in a town in
south-east Wales. Initially three cases were detected during
December 2011, all with onset dates within 9 days of each
other. No clear epidemiological links could be established
apart from time, place and that all were aged 44–55 years.
Two further cases from the same town were hospitalized, a
female aged 3 years and a female aged 47 years who was
admitted to critical care. A second cluster of three cases with
onset dates within 10 days of each other was detected in west
Wales during summer 2012, with one admission to hospital
from the same region.
The presenting features of community cases were indistin-
guishable from inﬂuenza-like illness, suggesting that M. pneu-
moniae, at times, may circulate unrecognized in the community.
Whether undiagnosed, sporadic, background circulation leads
to an increase in hospitalizations is yet to be determined,
although initial ﬁndings suggest there may be a temporal
association, especially where community clustering of cases
was observed; a larger study would provide more conclusive
information.
Data from Wales did not reﬂect the 2010–2012 northern
European M. pneumoniae epidemic due to the limited numbers
of cases tested by serology annually. Following the introduc-
tion of NAAT, the understanding and awareness of M. pneu-
moniae infection and epidemiology increased and so a NAAT
for M. pneumoniae should be considered an integral part of the
routine respiratory screening algorithm for both community
and hospital patients presenting with acute respiratory illness.
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